Home › Compare › LINUF vs PFE

LINUF vs PFE: Dividend Comparison 2026

LINUF yields 2000000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LINUF wins by $1.6247481716182984e+23M in total portfolio value
10 years
LINUF
LINUF
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full LINUF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — LINUF vs PFE

📍 LINUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLINUFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LINUF + PFE cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LINUF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LINUF
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, LINUF beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LINUF + PFE for your $10,000?

LINUF: 50%PFE: 50%
100% PFE50/50100% LINUF
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

LINUF
No analyst data
Altman Z
-2.2
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LINUF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLINUFPFE
Forward yield2000000.00% ✓6.13%
Annual dividend / share$2.00 ✓$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2% ✓
Portfolio after 10y$1.6247481716182984e+23M$49.6K ✓
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00 ✓$26,258.71
Total dividends collected$1.6146053563276882e+23M$58.3K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LINUF vs PFE ($10,000, DRIP)

YearLINUF PortfolioLINUF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$100,010,700$100,000,000.00$9,153$693.39+$100.00M → LINUF
2$467,446,731,075$467,339,719,626.17$8,593$849.25+$467446.72M → LINUF
3$1,021,215,363,816,662$1,020,715,195,814,411.90$8,336$1,066.78+$1021215363.81M → LINUF
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$8,437$1,384.80+$1043112617104.10M → LINUF
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$9,013$1,875.40+$498482143759731.38M → LINUF
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$10,306$2,680.72+$111599275650097776.00M → LINUF
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$12,820$4,101.38+$11738678336351557632.00M → LINUF
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$17,673$6,826.70+$583674362697175072768.00M → LINUF
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$27,543$12,591.86+$1.3894210989607547e+22M → LINUF
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$49,560$26,258.71+$1.6247481716182984e+23M → LINUF

LINUF vs PFE: Complete Analysis 2026

LINUF — Stock

LiNiu Technology Group, through its subsidiaries, engages in gaming related business. The company operates one VIP gaming room in one casino in Macau; and two casinos in Australia that are primarily focused on VIP baccarat. It also offers the LiNiu Network, a business to customer, customer to customer, and online to offline electronic trading platform focused on the Chinese agricultural industry. LiNiu Technology Group has a strategic cooperation agreement with The Peoples Insurance Company of China Limited's Guangzhou branch to develop insurance products for farmers, rural residents, and the agricultural industry. The company was formerly known as Iao Kun Group Holding Company Limited and changed its name to LiNiu Technology Group in April 2017. LiNiu Technology Group is based in Macau, Macau.

Full LINUF Calculator →

PFE — Healthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this LINUF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LINUF vs SCHDLINUF vs JEPILINUF vs OLINUF vs KOLINUF vs MAINLINUF vs JNJLINUF vs MRKLINUF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.